肠道支架植入术后卡培他滨联合恩度治疗晚期结肠癌的临床研究

详细信息    查看全文 | 推荐本文 |

英文篇名：Clinical efficacy of capecitabine combined with Endostar in the treatment of advanced colon cancer after stent implantation 作者：王帅兵 ; 郭茜 ; 武振明 ; 刘军 ; 齐秀恒 英文作者：Wang Shuaibing;Guo Qian;Wu Zhenming;Liu Jun;Qi Xiuheng;Petroleum Clinical Medical College of Hebei Medical University ,Department of Oncology,China National Petroleum Corporation Central Hospital; 关键词：结肠肿瘤 ; 支架 ; 肠梗阻 ; 卡培他滨 ; 恩度 ; 疗效 英文关键词：Colon neoplasms;;Stent;;Intestinal obstruction;;Capecitabine;;Endostar;;Efficacy 中文刊名：ZAZF 英文刊名：Chinese Journal of Oncology Prevention and Treatment 机构：河北医科大学石油临床医学院中国石油天然气集团公司中心医院肿瘤科; 出版日期：2018-10-25 出版单位：中国癌症防治杂志 年：2018 期：v.10 基金：廊坊市科技计划支撑项目(2014013006C) 语种：中文; 页：ZAZF201805004 页数：5 CN：05 ISSN：45-1366/R 分类号：22-26

摘要

目的探讨卡培他滨联合重组人血管内皮抑制素(恩度)治疗肠道支架植入术后的晚期结肠癌患者的疗效及安全性。方法选取2010年1月至2017年1月收治的不能手术切除且伴肠梗阻的晚期结肠癌患者79例,根据其后续治疗方案分为治疗组(39例)和对照组(40例)。所有患者入院后均行肠道支架植入术,解除肠梗阻后,治疗组给予卡培他滨联合恩度治疗,对照组给予卡培他滨单药治疗。治疗周期结束后比较两组的近期疗效和不良反应,并随访两组的无疾病进展生存期和总生存期。结果所有患者均成功植入肠道支架解除肠梗阻,并完成化疗计划。治疗组患者的总有效率较对照组高,但差异无统计学意义(46.15%vs 30.00%,χ~2=2.921,P=0.087);治疗组疾病控制率亦高于对照组,差异有统计学意义(69.23%vs 50.00%,χ~2=3.978,P=0.046)。两组患者化疗及肠道支架植入术相关不良反应发生率相当(P>0.05)。治疗组中位无疾病进展生存期较对照组延长3个月(16个月vs 13个月,P<0.05),中位总生存期延长6个月(25个月vs 19个月,P<0.05)。结论肠道支架植入术可有效解除结肠癌患者肠梗阻,后续卡培他滨联合恩度治疗的疗效优于卡培他滨单药治疗,且未增加不良反应,患者可耐受。
        Objective To investigate the efficacy and safety of capecitabine combined with recombinant human endostatin(Endostar)in the treatment of patients with advanced colon cancer after stent implantation. Methods A total of 79 patients with advanced colon cancer who were unable to undergo surgical resection and complicated with intestinal obstruction were recruited between January 2010 and January 2017. Patients were divided into control group(n=40)that received capecitabine alone or treatment group(n=39) that received capecitabine with Endostar. The short-term efficacy and adverse reactions were compared between the two groups,and the progression-free survival and overall survival were observed. Results All patients were successfully implanted with intestinal stents to remove the obstruction and completed the chemotherapies. The total response rate of the treatment group was higher than that in the control group(46.15% vs 30.00%),but there was no significant difference(χ~2=2.921,P=0.087),and the treatment group showed significantly higher disease control rate than that in the control group(69.23% vs 50.00%,χ~2=3.978,P =0.046). The incidence rate of adverse reactions associated with chemotherapy and intestinal stenting was similar between the two groups(P>0.05). Median progression-free survival was 16 months in the treatment group,significantly longer than 13 months in the control group(P<0.05). Similarly,median overall survival was 25 months in the treatment group,significantly longer than 19 months in the control group(P<0.05). Conclusions Intestinal stenting can effectively relieve intestinal obstruction in patients with colon cancer,and capecitabine combined with Endostar is superior to capecitabine alone.

引文

[1]袁红.自膨式金属支架与普通金属支架置入减压用于结肠癌伴梗阻的效果分析[J].结直肠肛门外科,2016,22(6):569-572.
    [2] Attar A,Maunoury V,Vahedi K,et al.Safety and efficacy of extractible self-expandable metal stents in the treatment of Crohn's disease intestinal strictures:a prospective pilot study[J].Inflamm Bowel Dis,2012,18(10):1849-1854.
    [3] Loras C,Perez-Roldan F,Gornals JB,et al.Endoscopic treatment with self-expanding metal stents for Crohn's disease strictures[J].Aliment Pharmacol Ther,2012,36(9):833-839.
    [4] Watt AM,Faragher IG,Griffin TT,et al.Self-expanding metallicstents for relieving malignant colorectal obstruction:a systematic review[J].Ann Surg,2007,246(1):24-30.
    [5]石磊,赵伟,周宇,等.肠道支架置入术与急诊手术治疗急性梗阻性结直肠癌疗效的Meta分析[J].中国全科医学,2016,19(8):941-945.
    [6] Xing P,Hao X,Hu X,et al.Recombinant human endostatin in the treatment of advanced lung squamous cell carcinoma[J].Zhongguo Fei Ai Za Zhi,2016,19(10):670-674.
    [7] Huang W,Liu J,Wu F,et al.The efficacy and safety of endostar combined with taxane-based regimens for HER-2-negative metastatic breast cancer patients[J].Oncotarget,2016,7(21):31501-31507.
    [8] Guan Y,Li A,Xiao W,et al.The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced,locally recurrent nasopharyngeal carcinoma[J].Oncotarget,2015,6(32):33926-33934.
    [9]任铁军,单风晓,侯建峰,等. XELOX方案联合恩度一线治疗晚期胆系肿瘤的临床观察[J].中国癌症防治杂志,2015,7(1):41-44.
    [10] Gao SR,Li LM,Xia HP,et al.Clinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancer[J].Asian Pac J Cancer Prev,2015,16(9):4037-4040.
    [11] Chen Z,Guo W,Cao J,et al.Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients:a phase I clinical tria[lJ]. Cancer Chemother Pharmacol,2015,75(3):547-557.
    [12] Li BL,Hu XL,Zhao XH,et al.Endostar combined with irinotecan/calcium folinate/5-fluorouracil(FOLFIRI)for treating advanced colorectal cancer:A clinical study[J].J Chemother,2015,27(5):301-306.
    [13]郭茜,齐秀恒,武振明,等.卡培他滨单药联合重组人血管内皮抑素(恩度)用于老年晚期结直肠癌一线化疗的研究[J].现代肿瘤医学,2017,25(6):25-28.